The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting pathologic bone destruction. In clinical trials, carfilzomib, a next generation epoxyketone-based irreversible PI, has exhibited potent anti-myel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hurchla, MA, Garcia-Gomez, A, Hornick, MC, Ocio, EM, Li, A, Blanco, JF, Collins, L, Kirk, CJ, Piwnica-Worms, D, Vij, R, Tomasson, MH, Pandiella, A, Miguel, JF San, Garayoa, M, Weilbaecher, KN
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771507/
https://ncbi.nlm.nih.gov/pubmed/22763387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.183
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars